KemPharm Rebrands as Zevra Therapeutics

KemPharm has actually altered its name to Zevra Rehabs, a nod to the uncommon illness neighborhood.

The brand-new name, Greek for “zebra,” is the worldwide identified icon for the neighborhood and also represents an increased concentrate on creating cutting-edge treatments for uncommon conditions with restricted or no readily available therapies, according to a news release from the business.

” The fostering of the name Zevra, the Greek word for zebra, is a crucial action in our trip to come to be a leading uncommon illness business considering that the zebra is the identified icon of the uncommon illness neighborhood worldwide,” claims Richard W. Pascoe, Chief Executive Officer of Zevra, in a news release. “With the launch of our brand-new business name in expectancy of Unusual Illness Day following week, we restore our undeviating dedication to stand with this vital neighborhood as we seek our key goal to supply life-altering therapies to individuals with uncommon problems, their households, and also caretakers that frantically require far better choices.”

Zevra is presently progressing KP1077, an item prospect based upon Zevra’s prodrug of d-methylphenidate, serdexmethylphenidate, which is being examined in a stage 2 test for the therapy of idiopathic hypersomnia, an unusual rest condition impacting less than 200,000 individuals in the United States, according to the National Institutes of Health And Wellness.

Pending the arise from that test, the business prepares to perform a critical stage 3 research study in idiopathic hypersomnia, with the possible to research an increased sign in narcolepsy.

In Addition, in Might 2022, Zevra, after that KemPharm, obtained arimoclomol, an orally-delivered, investigational item prospect for dealing with Niemann-Pick kind C illness, from Orphazyme A/S as component of the business’s lasting vision to progress right into a readily driven uncommon illness rehabs business. Niemann-Pick kind C is an unusual illness without presently accepted therapies in the United States, which mostly impacts kids and also is typically deadly.

” The Zevra group is proactively leveraging their deep clinical and also medical proficiency and also calculated strategy to get over medicine growth and also regulative obstacles to progress much-needed remedies to individuals that require them,” claims Matthew R. Plooster, chairman of the board of supervisors, in a news release. “Furthermore, we have the management group and also funds to obtain our appealing uncommon illness medicine prospects over the regulative authorization goal and also right into the United States market, which the board securely thinks will certainly be an essential value-driver for people and also investors alike.”

The business’s typical shares will certainly trade on the Nasdaq Global Select Market under the brand-new ticker icon “ZVRA” beginning on or concerning March 1, 2023.

Picture 40789025 © Gabriel Robledo| Dreamstime.com